GP leaders are reiterating their call for longer consultation times on the back of a new analysis showing that patients with multi-morbidities account for more than half of appointments.
News
Cancer Researck UK links with Ideaya on PARG inhibitors
Cancer Research UK is partnering with US biotech Ideaya Biosciences to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).
Speedy US review for MSD’s Keytruda in cervical cancer
US regulators will undertake a priority review of MSD’s Keytruda as a treatment for patients with advanced cervical cancer.
AbbVie, Neurocrine’s fibroid drug hits PhIII targets
A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.
Researchers discover ‘new line of attack’ on triple negative breast cancer
Scientists have uncovered a novel approach to fighting hard-to-treat breast cancers, triggering a new drug programme designed to develop novel targeted therapies for the disease.
Cancer drug study placed on hold after patient death
US regulators have placed on hold a clinical trial testing a combination of Advaxis’ axalimogene filolisbac and AstraZeneca’s Imfinzi after a patient died from respiratory failure.
SMC nod for Novartis’ Kisqali, MSD’s Keytruda
The Scottish Medicines Consortium (SMC has published new guidelines approving NHS funding for medicines for breast cancer and Hodgkin’s lymphoma.
SGLT-2 inhibitors cut risk of death in diabetics, data shows
AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
Biogen buys Pfizer’s schizophrenia drug
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
Hikma/Vectura’s generic Advair delayed in the US
US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline’s asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
Sanofi, Regeneron to cut price of Praluent
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
AZ announces results delay for key lung cancer trial
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
NICE minded to reject Keytruda for classical Hodgkin lymphoma
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.
EU expands scope of GSK/Innoviva’s asthma inhaler
The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach.
PharmaTimes Clinical Researcher of the Year – The Americas: Finalists to be announced soon!
Clinical researchers in the Americas have submitted essays for this year’s competition and on 15 March, the authors and finalists will be identified at a meeting of the executive steering group.
